MedTrace Logo

The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles

NCT03209687 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2026-03-19

No results posted yet for this study

Summary

The aim of this study is to test the hypothesis that addition of daily small dose of human menopausal gonadotropin (HMG) drug following oocytes retrieval could improve the fertility outcome in women undergoing in-vitro fertilization

Conditions

Interventions

DRUG

human menopausal gonadotropin

Merional injections will be given to participants after ovum pickup in in-vitro fertilization cycles

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Abdelmaguid Ramzy, M.D. · Cairo University

  • Eman Omran, M.D. · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-06
Primary Completion
2024-07-15
Completion
2024-08-15

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03209687 on ClinicalTrials.gov